Copanlisib
Aliqopa (copanlisib) is a small molecule pharmaceutical. Copanlisib was first approved as Aliqopa on 2017-09-14. It is used to treat follicular lymphoma in the USA. It is known to target phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform, serine/threonine-protein kinase mTOR, and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aliqopa | New Drug Application | 2023-09-07 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| follicular lymphoma | — | D008224 | C82 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
COPANLISIB DIHYDROCHLORIDE, ALIQOPA, BAYER HEALTHCARE | |||
| 2024-09-14 | ODE-155 | ||
HCPCS
Code | Description |
|---|---|
| J9057 | Injection, copanlisib, 1 mg |
Clinical
Clinical Trials
76 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 9 | 5 | — | — | — | 11 |
| Neoplasms | D009369 | — | C80 | 9 | 2 | — | — | 1 | 11 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 7 | 3 | — | — | — | 8 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 4 | 5 | — | — | — | 8 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | 4 | — | — | — | 5 |
| Follicular lymphoma | D008224 | — | C82 | 2 | 3 | — | — | — | 5 |
| B-cell lymphoma | D016393 | — | — | 3 | 3 | — | — | — | 5 |
| Prostatic neoplasms | D011471 | — | C61 | 3 | 3 | — | — | — | 4 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | 3 | — | — | — | 4 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | 2 | — | — | — | 4 |
Show 51 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 2 | — | — | — | — | 2 |
| Hodgkin disease | D006689 | — | C81 | 2 | — | — | — | — | 2 |
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | — | — | — | — | 2 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | — | — | — | — | 1 |
Show 23 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Copanlisib |
| INN | copanlisib |
| Description | Copanlisib, sold under the brand name Aliqopa, is a medication used for the treatment of adults experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies.
|
| Classification | Small molecule |
| Drug class | phosphatidylinositol 3-kinase (PI3K) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21 |
Identifiers
| PDB | — |
| CAS-ID | 1032568-63-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3218576 |
| ChEBI ID | — |
| PubChem CID | 24989044 |
| DrugBank | DB12483 |
| UNII ID | WI6V529FZ9 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
MTOR
MTOR
Organism
Homo sapiens
Gene name
MTOR
Gene synonyms
FRAP, FRAP1, FRAP2, RAFT1, RAPT1
NCBI Gene ID
Protein name
serine/threonine-protein kinase mTOR
Protein synonyms
FK506 binding protein 12-rapamycin associated protein 2, FK506-binding protein 12-rapamycin complex-associated protein 1, FKBP-rapamycin associated protein, FKBP12-rapamycin complex-associated protein, FKBP12-rapamycin complex-associated protein 1, Mammalian target of rapamycin, Mechanistic target of rapamycin, mechanistic target of rapamycin (serine/threonine kinase), mTOR, Rapamycin and FKBP12 target 1, rapamycin associated protein FRAP2, Rapamycin target protein 1
Uniprot ID
Mouse ortholog
Mtor (56717)
serine/threonine-protein kinase mTOR (Q9JLN9)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,797 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
356 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use